(0974–1003) SLE – Treatment Poster II

Sunday, November 13, 2022

9:00 AM – 10:30 AM Eastern Time

Location: Virtual Poster Hall

All of the relevant financial relationships listed for faculty have been mitigated.

Poster abstract session.

Presentations:

9:00 AM – 10:30 AM Eastern Time

Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Abstract Poster Presenter: Lucy Carter, PhD, BSc, MRCP – University of Leeds
9:00 AM – 10:30 AM Eastern Time

Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
Abstract Poster Presenter: Madhu Ramaswamy, PhD – ASTRAZENECA
9:00 AM – 10:30 AM Eastern Time

Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Abstract Poster Presenter: Alvaro Gomez, MD – Karolinska Institutet
9:00 AM – 10:30 AM Eastern Time

Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
Abstract Poster Presenter: Jason Knight, MD, PhD – University of Michigan
9:00 AM – 10:30 AM Eastern Time

Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus
Abstract Poster Presenter: Muhammad RA Shipa, MBBS, MRCP – University College London
9:00 AM – 10:30 AM Eastern Time

Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Abstract Poster Presenter: Francisco Sanchez-Guerrero, MD, MSc – University Health Network/Sinai Health system
9:00 AM – 10:30 AM Eastern Time

The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc
Abstract Poster Presenter: Kourtney Rudzinski, DO – Lehigh Valley Health Network
9:00 AM – 10:30 AM Eastern Time

QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine - Preliminary Results from a Single Center Study
Abstract Poster Presenter: Tanmayee Bichile, MD – Allegheny Health Network
9:00 AM – 10:30 AM Eastern Time

Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Abstract Poster Presenter: Jordan Jacquez, MD – UCLA
9:00 AM – 10:30 AM Eastern Time

Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Poster Presenter: Jake Altier, MD – Medical University of South Carolina
9:00 AM – 10:30 AM Eastern Time

Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications
Abstract Poster Presenter: Colin Mowery, BSc, -None- – University of Oklahoma College of Medicine
9:00 AM – 10:30 AM Eastern Time

S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE
Abstract Poster Presenter: Risa Wakiya, MD, PhD – Kagawa University
9:00 AM – 10:30 AM Eastern Time

Impact of Weight and Race on Renal Response to Cyclophosphamide in the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS)
Abstract Poster Presenter: Julia Ford, MD – University of Michigan
9:00 AM – 10:30 AM Eastern Time

A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Abstract Poster Presenter: Stacey Dillon, PhD – Alpine Immune Sciences
9:00 AM – 10:30 AM Eastern Time

Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran
Abstract Poster Presenter: Cristina Vazquez Mateo, PhD – EMD Serono
9:00 AM – 10:30 AM Eastern Time

Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
Abstract Poster Presenter: Nandita Sarkar, PhD – Amgen
9:00 AM – 10:30 AM Eastern Time

KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with SLE: Results of a Phase Ib Multiple Ascending Dose Study
Abstract Poster Presenter: Robert W. Levin, MD – Robert W Levin MD PA
9:00 AM – 10:30 AM Eastern Time

Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
Abstract Poster Presenter: Cassandra Calabrese, DO – Cleveland Clinic Foundation
9:00 AM – 10:30 AM Eastern Time

Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Abstract Poster Presenter: Amit Saxena, MD – NYU School of Medicine
9:00 AM – 10:30 AM Eastern Time

SARS-CoV-2 Vaccine Side Effects and Infections in SLE
Abstract Poster Presenter: Laura Yan, MD – McGill University
9:00 AM – 10:30 AM Eastern Time

Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus
Abstract Poster Presenter: Michelle Petri, MD, MPH – Johns Hopkins University School of Medicine
9:00 AM – 10:30 AM Eastern Time

Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus
Abstract Poster Presenter: Patricia Katz, PhD – UCSF
9:00 AM – 10:30 AM Eastern Time

Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
Abstract Poster Presenter: Jiacai Cho, MBBS, MRCP, MMed – National University Hospital
9:00 AM – 10:30 AM Eastern Time

Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among Patients with Systemic Lupus Erythematosus in Long Term Clinical Remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial
Abstract Poster Presenter: Aishwarya Gopal, MD, MBBS – Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)
9:00 AM – 10:30 AM Eastern Time

A Real-world Analysis Showing Significant Variance in Treatment Patterns Among over 1,000 Systemic Lupus Erythematosus (SLE) Patients in the US
Abstract Poster Presenter: Ryan Rex, BS – Spherix Global Insights
9:00 AM – 10:30 AM Eastern Time

WITHDRAWN
9:00 AM – 10:30 AM Eastern Time

Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
Abstract Poster Presenter: Ian Catlett, PhD – Bristol Meyers Squibb
9:00 AM – 10:30 AM Eastern Time

Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
Abstract Poster Presenter: David Isenberg, MD, FRCP – University College London
9:00 AM – 10:30 AM Eastern Time

Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P₁ Receptor Modulator Cenerimod
Abstract Poster Presenter: Daniel Strasser, PhD, PharmD – Idorsia Pharmaceuticals Ltd.
9:00 AM – 10:30 AM Eastern Time

Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement
Abstract Poster Presenter: Coral Mourino Rodriguez, RN – Hospital Meixoeiro